Senesco Technologies to Present at the 14th Annual Meeting of American Society of Gene and Cell Therapy

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT), announced today that it will deliver a poster presentation at the 14th Annual Meeting of the American Society of Gene & Cell Therapy. The conference will be held May 18-21, 2011 at the Washington State Convention Center in Seattle, Washington. The Company will present during the Late Abstract Session II, which will begin Friday, May 20, at 4:40 P.M. Eastern Time. The poster presentation, entitled “Optimization of DNA to siRNA Ratio in SNS01 – an eIF5A-Based Gene Therapy Nanoparticle Designed for the Treatment of Multiple Myeloma”, will describe the properties of SNS01-T and be delivered by Catherine Taylor, from Senesco CSO John Thompson’s research laboratory at the University of Waterloo in Ontario, Canada. Additional details about the conference can be found at: http://www.asgct.org

About Senesco Technologies, Inc.

Senesco Technologies is leveraging proprietary technology that regulates programmed cell death, or apoptosis. Accelerating apoptosis may have application in treating cancer, while delaying apoptosis may have application in certain inflammatory and ischemic diseases. The Company is preparing to initiate a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners’ products.

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company’s ability to comply with the continued listing standards of the NYSE/AMEX, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.